Apellis Pharmaceuticals, Inc. (APLS)

40.96 +0.01 (+0.02%) USD  |  NASDAQ  |  May 01, 12:39
More

Apellis Pharmaceuticals Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for APLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
Biogen, Inc. Upgrade
Eli Lilly & Co. Upgrade
Agios Pharmaceuticals, Inc. Upgrade
Scholar Rock Holding Corp. --
Kezar Life Sciences, Inc. --